Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | I Dolado, U Fiedler, H Strobel, C Metz, MT Stumpp and L Rojkjaer | ||||||||||||
Title | A bivalent Her2 targeting DARPin with high efficacy against Her2-low and Her2-positive tumors | ||||||||||||
|
|||||||||||||
URL | https://cancerres.aacrjournals.org/content/73/24_Supplement/P4-12-30 | ||||||||||||
Abstract Text | Cancer Res 2013;73(24 Suppl): Abstract nr P4-12-30. |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MP0274 | MP 0274|MP-0274 | HER2 (ERBB2) Antibody 72 | MP0274, is a bivalent designed ankyrin repeat protein (DARPin) that specifically binds Erbb2 (Her2), which potentially inhibits Erbb2 (Her2) and Erbb3 (Her3) signaling, leads to apoptosis and tumor growth inhibition (Cancer Res 2013;73(24 Suppl): Abstract nr P4-12-30). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|